For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress

Featuring a slide presentation from Dr Julia Rotow, including the following topics: Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00) Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12) Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59) Clinician insights about the potential role of ivonescimab in the front-line setting (12:02) Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01) Key findings from the Phase III HARMONi-A and HARMONi studies (16:07) Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)

Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) EGFR Mutations (2:23) HER2 Alterations (22:40) Available and Investigational Immunotherapies (32:14) Small Cell Lung Cancer (40:48)

Featuring an interview with Dr Alexander E Drilon, including the following topics: Overview of targetable biomarkers in lung cancer (0:00) Biomarker testing for genomic alterations in lung cancer (5:24) Overview of ROS1 alterations in lung cancer (13:44) Efficacy data with ROS1 inhibitors for lung cancer (17:02) Safety data with ROS1 inhibitors for lung cancer (21:15) Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56) Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16) Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)

Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics: Introduction (0:00) Best Option for Your Patient (1:28) Biological Considerations (6:26) KRAS G12C Inhibitors (11:33) Second-Line Treatment (13:02) Current Clinical Trials in the First-Line Metastatic Setting (32:18) Current Clinical Trials in the Localized Setting (49:52) Current Clinical Trials with New Treatment Combinations and Agents (53:51)

Featuring an interview with Prof Ticiana Leal, including the following topics: Pathophysiology and clinical signs and symptoms (0:00) Screening and/or diagnostic approaches (5:45) Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36) Key clinical trial data for amifampridine and practicalities of its administration (14:05) Building awareness among patients, caregivers and the oncology community (22:37) Role of pyridostigmine in managing Lambert-Eaton myasthenic syndrome (LEMS); potential integration of EMG (electromyography) into monitoring (25:35) Case: A man in his early 70s who receives a diagnosis of limited-stage SCLC (LS-SCLC) with LEMS and undergoes treatment (27:41) Case: A woman in her late 70s already diagnosed with LS-SCLC who is subsequently evaluated and treated for LEMS (37:55) Current research and potential developments in the treatment of SCLC (48:32)